Table 2 Characteristics of pathologic patients grouped for disease.

From: Potential impact of a nonavalent anti HPV vaccine in Italian men with and without clinical manifestations

Parameters

Group I

200 men with presence of clinical symptoms

Group II

309 men with a risky sexual contact (STD)

Group III

466 men with HPV positive partner

Statistical analysis among groups

HPV + 

69% (138/200)

44.3% (137/309)

63.7% (297/466)

p < 0.0001* (C)

Group I**, p = 0.0098 (Z)

Group II***, p < 0.0001 (Z)

Age (HPV +)

35.38 ± 10.40

38.61 ± 10.79

36.04 ± 9.50

p = 0.015* (A)

Group II > Group I, p < 0.05* (S)

Group II > Group III, p < 0.05* (S)

HR-HPV

69.6% (96/138)

78.1% (107/137)

84.5% (251/297)

p = 0.0015* (C)

Group I***, p = 0.0169 (Z)

LR-HPV

30.43% (42/138)

21.90% (30/137)

15.49% (46/297)

p = 0.0015* (C)

Group I**, p = 0.0169 (Z)

Total single HPV

54.3% (75/138)

46.7% (64/137)

47.1% (140/297)

p = 0.322 (C)

Total multiple HPV

45.6% (63/138)

53.3% (73/137)

52.9 (157/297)

p = 0.322 (C)

 2 HPV genotype

50.8% (32/63)

35.6% (26/73)

47.1% (74/157)

p = 0.154 (C)

 3 HPV genotype

19% (12/63)

26% (19/73)

26.7% (42/157)

p = 0.475 (C)

 4 HPV genotype

12.7% (8/63)

26.% (19/73)

15.9% (25/157)

p = 0.087 (C)

 5 HPV genotype

7.9% (5/63)

6.8% (5/73)

7% (11/157)

p = 0.964 (C)

 6 HPV genotype

3.2% (2/63)

2.7% (2/73)

1.9% (3/157)

p = 0.836 (C)

 7 HPV genotype

4.8% (3/63)

0.00% (0/73)

1.3% (2/157)

p = 0.084 (C)

 8 HPV genotype

1.6% (1/63)

1.4% (1/73)

0.00% (0/157)

p = 0.309 (C)

 9 HPV genotype

0.00% (0/63)

1.4% (1/73)

0.00% (0/157)

p = 0.221 (C)

Vaccine impact quadrivalent genotype

Low impact

29.7% (41/138)

19.7% (27/137)

15.1% (45/297)

p = 0.0018* (C)

Group I**, p = 0.0137 (Z)

High impact

28.3% (39/138)

31.4% (43/137)

23.2% (69/297)

p = 0.171 (C)

Vaccine impact nonavalent genotype

Low impact

35.5% (49/138)

31.4% (43/137)

26.3% (78/297)

p = 0.129 (C)

High impact

32.1% (45/138)

38% (52/137)

33.7% (100/297)

p = 0.60 (C)

% AAI

10.1% (14/138)

18.2% (25/137)

21.5% (64/297)

p = 0.0157* (C)

Group I***, p = 0.0458 (Z)

% RAI

17.5% (14/80)

35.7% (25/70)

56.1% (64/114)

p < 0.0001* (C)

Group III**, p = 0.0059 (Z)

Group I***, p = 0.0007 (Z)

  1. AAI absolute additional impact, RAI relative additional impact, clinical symptoms condiloma, atypical lesions.
  2. *Significant test, **most frequent, ***less frequent; C = multiple comparison χ2 test; Z = Z-test; A = one way Anova test; S = Scheffé test for pairwise comparisons, post hoc Anova test.
Back to article page